A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO)

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 11, 2017, Pages 3177-3180

  Barker, Anna K ^a   Duster, Megan ^a   Valentine, Susan ^a   Hess, Timothy ^a   Archbald Pannone, Laurie ^b   Guerrant, Richard ^b   Safdar, Nasia ^a,c,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT DURATION; BIFIDOBACTERIUM ANIMALIS; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FECES; LACTOBACILLUS; MICROBIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM ANIMALIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMBINED MODALITY THERAPY; DIARRHEA; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; LACTOBACILLUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS;

EID: 85036625569     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx254     Document Type: Article

References (19)

1. Lessa FC, Mu Y, BambergWMet al. Burden of Clostridiumdifficile infection in the United States. NEngl JMed2015; 372: 825-34
2. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-90
3. Pepin J, Alary M-E, Valiquette L et al. Increasing risk of relapse after treatment of Clostridiumdifficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7
4. Norén T, Akerlund T, Bäck E et al. Molecular epidemiology of hospitalassociated and community-acquired Clostridium difficile infection in a Swedish county. J ClinMicrobiol 2004; 42: 3635-43
5. Hill C, Guarner F, Reid G et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-14
6. WHO, Food and Agriculture Organization of the United Nations. Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation. 2006. ftp://ftp. fao. org/docrep/fao/009/a0512e/a0512e00. pdf
7. Lee CH, Steiner T, Petrof EO et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016; 315: 142-9
8. Forestier C, De Champs C, Vatoux C et al. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. ResMicrobiol 2001; 152: 167-73
9. Schneider S-M, Girard-Pipau F, Filippi J et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 2005; 11: 6165-9
10. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. AmJ Physiol Gastrointest Liver Physiol 2010; 298: G807-19
11. Goldenberg JZ, Ma SSY, Saxton JD et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; issue 5: CD006095
12. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-22
13. Hempel S, Newberry SJ, Maher AR et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and metaanalysis. JAMA 2012; 307: 1959-69
14. Ritchie ML, Romanuk TN. Ameta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012; 7: e34938
15. Barker A, Duster M, Valentine S et al. Probiotics for Clostridium difficile infection in adults (PICO): study protocol for a double-blind, randomized controlled trial. Contemp Clin Trials 2015; 44: 26-32
16. Riegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol 2001; 5: 163-4
17. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md StateMed J 1965; 14: 61-5
18. Dubberke ER, Carling P, Carrico R et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35 Suppl 2: S48-65
19. PalssonOS, Baggish JS, TurnerMJ et al. IBS patients showfrequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. AmJ Gastroenterol 2012; 107: 286-95